Research progress in therapies for ischemic cerebrovascular diseases
10.3760/cma.j.cn121382-20220221-00414
- VernacularTitle:缺血性脑血管病治疗方法的研究现状
- Author:
Dongliang WANG
1
;
Yanfen DU
;
Xin LI
Author Information
1. 天津医科大学第二医院神经内科，天津 300211
- Keywords:
Cerebral vascular disease;
Thrombolysis;
Antiplatelet aggregation;
Plasma fibrinogen degradation;
Anti-freezing
- From:
International Journal of Biomedical Engineering
2022;45(4):362-367
- CountryChina
- Language:Chinese
-
Abstract:
Ischemic cerebrovascular disease (ICVD) is the most common type of nervous system disease in clinical practice in China at present. It is the important leading cause of death after heart disease and tumors. Ischemic cerebrovascular disease has a high rate of occurrence and mortality. It is easy to cause problems such as limb dysfunction, language disorders, nerve dysfunction, etc. It has a great negative effect on the quality of life of patients, and seriously affects the quality of their lives. Although the current research on the treatment of the disease has achieved certain results, single therapies can only treat some key parts of the disease and cannot completely reverse the whole process. At present, thrombolysis, antiplatelet aggregation, degradation of plasma fibrin, anticoagulation, and hemodilution are mainly used in clinical treatment. It is critical to select appropriate treatment methods based on the pathological characteristics of patients to improve efficacy and prognosis. In this review, the research progress in therapies for ischemic cerebrovascular disease was reviewed, both at home and abroad.
